CD274 and Miyoshi myopathy: In MM, the PD1/PDL1 blockade was not effective in the relapsed setting as monotherapy, and the subsequent phase III trials (KEYNOTE-185 and KEYNOTE-183) in combination with immunomodulatory agents had to be halted by the FDA because of an increase in deaths in the pembrolizumab arm.